GENE ONLINE|News &
Opinion
Blog

2018-05-29| ChinaFundingStartups

Beijing AI+Blockchain Pharma Startup Received Millions of USD Pre-A Financing

by GeneOnline
Share To

Deep Intelligent Pharma (DIP), a company integrating artificial intelligent (AI) technology with pharmaceutical development, received millions of US dollar from ZhenFund, a Beijing-based seed capital, in its pre-A round financing last December. This message was released by a spokesperson at DIP on May 24.

By Joanne Shih

DIP is a technology start-up launched in Beijing in October 2017, applying AI and blockchain technologies to facilitate drug discovery, development, and medical regulatory affairs. Established in China, the company sets its headquarters in Beijing, but branches in both China and the US with offices in Shanghai, Shenyang, Boston, and Silicon Vally. Currently, DIP has over 50 full-time employees.

The company has launched around ten products and collaborated with several Chinese, Asia Pacific, and global pharmaceutical companies since its establishment. Aiming to empower advancement in medical and pharmaceutical industries, DIP has six major product lines which respectively are: 1) Intelligent Pharmacovigilance, 2) A.I.M AI IN MEDICAL, 3) A Blockchain-based, Patient-research Ecosystem, 4) Intelligent Medical Writing, 5) Medical Translations, and 6) Intelligent Regulatory Affairs Solution. Among these products, AI and blockchain play a pivot role in creating new platforms for medical and clinical research and in allowing medical data to be used appropriately.

Emma Yin, Investment Vice President at ZhenFund, said, “DIP is formed by a talented pool from international pharmaceutical giants including Johnson & Johnson, Pfizer, Eli Lilly, Novartis, as well as AI algorithmists from Alibaba and experts in natural language processing. It is a true combination of AI technology and drug R&D. Therefore, DIP has the potential to develop viable solutions and meet demands in pharmaceutical market.”

Reference

https://ibmi.taiwan-healthcare.org/news_detail.php?REFDOCTYPID=&REFDOCID=0p99g009btfcwvn

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
MedTex Summit Asia 2022: Revolutionizing Smart Healthcare with Next Generation Technologies
2022-12-09
35% of Americans May Avoid Seeking Care Due to Concerns Over Healthcare Prices
2022-10-31
Thermo Fisher Announces $59 Million Lab Expansion In Kentucky, Reveals AI Deal With Genoox
2022-10-28
LATEST
Kite’s Yescarta Yields a Success in a Phase 3 Trial for Treating Large B-Cell Lymphoma
2023-03-22
Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
2023-03-22
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
2023-03-21
Comparing ESG Regulations in the U.S., the U.K., and the EU
2023-03-21
See-Mode Technologies Secures Regulatory Approvals for its AI-powered Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans in Australia and New Zealand
2023-03-21
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
2023-03-21
Scroll to Top